In 53 patients with stage II–IVB nasopharyngeal carcinoma after chemoradiotherapy, consolidation pembrolizumab did not improve 3-year PFS vs placebo (56.5% vs 57.8%; one-sided p=0.142). Grade ≥3 adverse events occurred only with pembrolizumab (8.8%).
RCTn = 53
Chun et al. Randomized Phase II Trial of Consolidation Pembrolizumab After Definitive Chemoradiotherapy in Locally Advanced Nasopharyngeal Carcinoma: KCSG HN19-09, CONPELAN Study